Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Wednesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently commented on the stock. Royal Bank of Canada decreased their price objective on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating for the company in a research report on Friday, October 25th. Jefferies Financial Group reissued a “hold” rating and set a $0.50 price target (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research report on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. TD Cowen reissued a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Marinus Pharmaceuticals stock opened at $0.54 on Wednesday. The company has a market cap of $30.00 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. The firm has a 50-day moving average of $0.40 and a 200-day moving average of $0.95. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $10.50.

Institutional Trading of Marinus Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Suvretta Capital Management LLC boosted its stake in shares of Marinus Pharmaceuticals by 32.8% in the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares during the period. Franklin Resources Inc. grew its holdings in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock worth $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. abrdn plc raised its stake in Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares in the last quarter. GSA Capital Partners LLP lifted its position in Marinus Pharmaceuticals by 409.4% during the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock worth $1,789,000 after purchasing an additional 817,050 shares during the period. Finally, Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals during the second quarter worth about $727,000. Institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.